Recent Updates
Recently added Catalysts
CGON Positive Sentiment

UROLOGY TIMES

Tuesday, March 25, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology's Cretostimogene grenadenorepvec continues to demonstrate positive efficacy and safety in its ongoing clinical evaluations. Recent updates include favorable results from the CORE-1008 Phase 2 trial, which focuses on high-risk patients. The company is also preparing for upcoming investor conferences and has announced fellowship award recipients for bladder cancer research.
Price reaction · baseline $28.53 (2025-03-24 close) · hit pre-market · 2 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-3.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Cretostimogene grenadenorepvec shows favorable efficacy.
  • The safety profile remains strong.
  • Positive results reported from CORE-1008 trial.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Mar 25, 2025 | in-the-news
Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What is Cretostimogene grenadenorepvec?

Cretostimogene grenadenorepvec is a therapeutic agent evaluated for its efficacy and safety in treating bladder cancer.

What were the results of the CORE-1008 trial?

The CORE-1008 Phase 2 trial reported positive results in high-risk BCG-exposed and BCG-unresponsive patients.

What upcoming events is CG Oncology participating in?

CG Oncology is set to present at several investor conferences in June.

What is the focus of the NMIBC Research Fellowship Award?

The NMIBC Research Fellowship Award supports research in non-muscle invasive bladder cancer.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology Cretostimogene grenadenorepvec bladder cancer CORE-1008 clinical trials
Last updated: Mar 25, 2025

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →